Is low-dose lorazepam (Ativan) safe during the first trimester of pregnancy?

Low-Dose Lorazepam in First Trimester: Avoid If Possible

Lorazepam should be avoided during the first trimester of pregnancy whenever possible, though available evidence does not definitively establish major teratogenic risk. The FDA drug label explicitly states that benzodiazepines cross the placenta and may cause fetal harm, and the manufacturer recommends against use particularly in early pregnancy 1.

Evidence Assessment

FDA Drug Label Guidance (Highest Priority)

The official Ativan (lorazepam) prescribing information provides critical warnings 1:

• Neonatal risks are well-established: Benzodiazepines cross the placenta and can cause respiratory depression, hypotonia, sedation, and withdrawal symptoms in neonates
• First trimester concerns: While the label notes that published observational studies "do not report a clear association with benzodiazepines and major birth defects," it emphasizes that all pregnancies carry baseline risk and caution is warranted
• Animal data showed anomalies: At higher doses in rabbits, occasional anomalies were observed (reduction of tarsals, tibia, metatarsals, malrotated limbs, gastroschisis, malformed skull, microphthalmia), plus fetal resorption

Clinical Guidelines Support Avoidance

Multiple specialty guidelines consistently recommend avoiding benzodiazepines in the first trimester when possible:

• Antihistamine guidelines (2007) state: "It is best to avoid all antihistamines in pregnancy, especially during the first trimester" and note that hydroxyzine is specifically contraindicated in early pregnancy 2
• Cardiac arrhythmia guidelines (2003,2016) recommend that "antiarrhythmic drugs should be avoided in the first trimester, when risk of congenital malformations is greatest" and note benzodiazepines should generally be avoided, particularly in first trimester 3, 4
• IBD in pregnancy guidelines (2016) recommend benzodiazepines be avoided, particularly in first trimester, though acknowledge a meta-analysis suggested benzodiazepines "do not appear to be associated with an increased teratogenic risk" while case-control studies suggest 2-fold increased risk of oral cleft 5

Research Evidence Shows Mixed Results

The research literature presents conflicting findings:

Studies suggesting minimal risk:

• A 2014 UK population-based cohort study found no evidence for increased major congenital anomalies (MCAs) with first-trimester benzodiazepine exposure: 2.7% MCA rate with diazepam vs 2.7% in unexposed controls (adjusted OR 1.02,99% CI 0.63-1.64) 6
• A 1994 review concluded that "in most studies involving first trimester use of benzodiazepines, the majority of infants were normal at birth and had normal postnatal development" 7
• A 2000 Canadian review stated "evidence to date from cohort studies did not identify a notable association between use of benzodiazepines and increased risk of major malformations" 8

Studies suggesting potential risks:

• A 2024 Taiwan study found benzodiazepine use associated with increased miscarriage risk (OR 1.69,95% CI 1.52-1.87), with lorazepam specifically showing OR 1.39 9
• A 2025 Taiwan study found associations with preterm birth (RR 1.20) and possibly small for gestational age (RR 1.06) 10
• A 2003 French registry study identified a potential association between lorazepam and anal atresia (OR 6.2,95% CI 2.4-15.7), though this was preliminary and unconfirmed 11

Clinical Decision Algorithm

Step 1: Assess Severity and Necessity

• Is the anxiety causing significant functional impairment or safety risk?
• Can non-pharmacologic interventions suffice (cognitive behavioral therapy, relaxation techniques)?
• Is this acute situational anxiety or chronic disorder requiring ongoing treatment?

Step 2: If Medication Required

• First-line alternatives: Consider SSRIs (sertraline, fluoxetine) which have more robust pregnancy safety data
• Second-line: If benzodiazepine absolutely necessary, use lowest effective dose for shortest duration
• Avoid chronic daily use: Intermittent as-needed dosing minimizes fetal exposure

Step 3: If Lorazepam Already Taken

• Do not panic: Absolute risk increase appears small based on cohort studies
• Obtain level 2 ultrasound at 18-20 weeks to evaluate for oral clefts and other structural anomalies 8
• Monitor for miscarriage risk in early pregnancy, though causation unclear

Step 4: Ongoing Management

• Taper and discontinue as soon as clinically feasible
• Do not abruptly stop if patient has been on chronic therapy (withdrawal risk)
• Plan for neonatal monitoring at delivery if use continues into third trimester

Critical Caveats

Neonatal withdrawal is the clearest risk: If lorazepam use continues into late pregnancy, neonates require monitoring for sedation, respiratory depression, hypotonia, feeding difficulties, and withdrawal symptoms (hyperreflexia, irritability, tremors, inconsolable crying) 1.

Dose matters: The studies showing minimal risk typically involved therapeutic doses. Higher doses or chronic use may carry different risk profiles.

Timing is critical: The greatest concern for structural malformations is weeks 3-8 of gestation (organogenesis). Exposure after this window primarily raises concerns about growth, neurodevelopment, and neonatal adaptation rather than major structural defects.

Individual context: A patient with severe panic disorder at risk of self-harm may have a different risk-benefit calculation than someone with mild situational anxiety.